ArticlePloS one2025
The role of Methyl-CpG binding domain 3 (Mbd3) protein in epileptogenesis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methyl CpG binding domain 3 (Mbd3) protein belongs to the MBD family of proteins and is responsible for reading the DNA methylation pattern. Our previous study revealed increased levels of Nucleosome Remodeling and Deacetylase (NuRD) complex proteins, including Mbd3, in the brains of epileptic animals. The present study investigated whether the Mbd3 protein level determines the seizure threshold. We demonstrate that seizures induced by pentylenetetrazole (PTZ) cause a transient, brain area-specific increase in Mbd3 protein levels in the entorhinal cortex and amygdala. Overexpression of Mbd3 in the amygdala using AAV decreased anxiety, increased excitability in the open-field test, and accelerated epileptogenesis in the PTZ-kindling model. In vitro, mRNA profiling using RNA-seq in a model of magnesium deficiency-induced epileptiform discharges revealed complex, time- and state-specific changes in gene expression. Genes regulated by Mbd3 overexpression were associated with the Wnt and Notch pathways, potassium channel function, and GABAB receptor signaling. Our findings indicate that increased Mbd3 expression has pro-epileptic properties and contributes to the regulation of multiple pathways potentially involved in seizure development. Significantly, seizures themselves transiently elevate Mbd3 levels, suggesting a potential vicious circle that may aggravate disease progression. Targeting the pro-epileptic effects of Mbd3 could therefore represent a novel therapeutic approach in epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.